Dopaminergic modulation of express reaching responses in Parkinson’s disease
Objective: This study investigates the role of dopamine (DA) in modulation of automatic stimulus-driven responses. We investigated the effect of PD, DA medication, and instruction…Do Parkinson’s disease medications have an effect on gut microbiome? A case-control study
Objective: To investigate the difference in the gut microbiota between drug-naïve and medicated PD patients and focus on the association between gut microbiota and anti-PD medications. Background:…Parkinson’s disease patients with hallucinations exhibit dopaminergic degeneration and cortical thinning
Objective: Examine whether Parkinson’s disease patients (PD) who experience hallucinations (PD+hall) exhibit a greater decline in striatal dopamine and corresponding posterior cortical decline relative to…Multimodal, longitudinal investigation in Dopa-responsive dystonia
Objective: To perform a detailed longitudinal clinical and neurophysiological investigation in monogenic Dopa-responsive dystonia (DRD) patients with mutations in the guanosine triphosphate cyclohydrolase 1 (GCH1)…Is Generalized and Segmental Dystonia Accompanied by Impairments of the Dopaminergic System?
Objective: To investigate functional dopaminergic impairments in dystonia, we compared patients with dystonia and Parkinson’s disease (PD) with normal controls using neuromelanin-sensitive magnetic resonance imaging…Connectomic Analysis of SNc and VTA Projections to the Striatum and Cortex
Objective: To investigate the dopaminergic neural tracts of healthy individuals using Diffusion MRI on Human Connectome Project Data. Background: Classically, the DA system has been…The effects of acute administration of VMAT2 inhibitors on extracellular levels of dopamine, norepinephrine, 5-HT and histamine in the striatum and medial prefrontal cortex
Objective: To evaluate the effects of reversible VMAT2 inhibitors (deutetrabenazine, tetrabenazine and valbenazine) on extracellular levels of monoamines and their acidic metabolites in rat striatum…Istradefylline/L-DOPA combination therapy for Parkinson’s disease and blood markers of glycolytic energy homeostasis
Objective: To clarify the potential to preserve glycolytic energy homeostasis (GEH) with the Istradefylline combined to L-DOPA (IST-LD), and to prevent LD-induced weight loss and…OPTIMIPARK Questionnaire:a tool to optimize treatment in Parkinson´s disease.
Objective: To validate the OPTIMIPARK questionnaire as a tool to help the clinician in the adjustment of dopaminergic treatment in Parkinson´s disease(PD). Background: At early…Influence of Dopamine Transporter Gene Polymorphism on Wearing Off
Objective: To study the influence of Dopamine transporter gene polymorphism on Wearing off (WO) through 19 items wearing off questionnaire (WOQ-19) Background: The dopamine transporter…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 24
- Next Page »